Stockreport

Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors [Yahoo! Finance]

Innate Pharma S.A. - American Depositary Shares  (IPHA) 
PDF The Phase 1, open-label, multi-center study, includes a Part 1 Dose Escalation and a Part 2 Dose Optimization, and will assess the safety, tolerability, and preliminary [Read more]